KARACHI – Martin Dow Marker Limited Pakistan (the Company) has been assigned a long-term rating of A+ and short-term rating of A1 with a stable outlook by PACRA.
Martin Dow Marker Limited is a notable name in the pharmaceutical segment of Pakistan operating since 1951. The Company operates under the umbrella of Martin Dow Group, one of the largest locally owned pharmaceutical Groups.
Expressing his views after the announcement, Mr. Javed Ghulam Mohammad, Group Managing Director & CEO of Martin Dow said, “With an uninterrupted legacy of over half a century, Martin Dow Group is benchmarked to deliver quality products that continue to contribute to the health of millions of people across the globe. We are proud to have received the long-term credit rating of A+ and short-term rating of A1 by PACRA, reflecting positively on the high standards of our operations.”
The Company has diversified portfolio with large manufacturing footprint in Pakistan. It markets research-based products through strategic alliances with global pharmaceutical groups and selling world-class branded generics which are developed, formulated and manufactured at its state-of-the-art cGMP compliant manufacturing facilities located in Quetta and Karachi. Over the years, the Company has achieved impressive growth profile and has positioned itself among the top 10 leading pharmaceutical companies of the industry. The Company is delivering sustainable business operations and have aggressive growth plan covering introduction of innovative technologies and products and expanding geographical reach through export of pharmaceutical products from Pakistan.
Martin Dow group is a leading multinational healthcare group in Pakistan with international presence and markets over 100 brands with more than 3000 employees countrywide.
At Martin Dow, we believe that Human Capital plays a pivotal role in our organization’s sustainable growth. We are making this possible with the focus on talent development through various learning, engagement and organizational development initiatives helping us to develop future leaders for Pharma industry and Pakistan at large. Our focus has been at embracing robust performance driven culture and implementing strategies that ensure the well-being of our employees.
Martin Dow has also been contributing to sustainable causes by playing an essential role in building a positive connection with the community. Our philanthropic activities are an intrinsic part of the Company’s DNA and our Corporate Social Responsibility model emanates from our core value of living with and giving back to the community, with prime focus on health, education and the environment.
Expressing his views after the announcement, Mr. Javed Ghulam Mohammad, Group Managing Director & CEO of Martin Dow said, “With an uninterrupted legacy of over half a century, Martin Dow Group is benchmarked to deliver quality products that continue to contribute to the health of millions of people across the globe. We are proud to have received the long-term credit rating of A+ and short-term rating of A1 by PACRA, reflecting positively on the high standards of our operations.”
